Cure Today3 天
The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...
Verywell Health on MSN2 天
Injectable Alzheimer's Drugs Could Save Patients Trips to the Hospital
Fact checked by Nick Blackmer The recent approvals of Leqembi (lecanemab) and Kisunla (donanemab) have refreshed the ...
Cure Today10 天
Delving into Subcutaneous Versus Intravenous Opdivo in Solid Tumors
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for ...
healthday6 小时
Fewer Bleeding Events Seen With Abelacimab Than Rivaroxaban in A-Fib
Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...
pharmaphorum9 天
FDA sets August date for subcutaneous Leqembi decision
To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...
ophthalmologytimes8 天
Ashvattha Therapeutics secures $50M in financing to advance clinical trials
The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in ...
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...